USNA Quote, Financials, Valuation and Earnings

BellRing Brands, Inc. has a net margin of -3.12% compared to USANA Health Sciences, Inc.'s net margin of 9.2%. USANA Health Sciences, Inc.'s return on equity of 3.06% beat BellRing Brands, Inc.'s return on equity of --.

USANA Health Sciences, Inc. has a consensus price target of $39.00, signalling upside risk potential of 82.5%. On the other hand BellRing Brands, Inc. has an analysts' consensus of $35.79 which suggests that it could grow by 44.41%. Given that USANA Health Sciences, Inc. has higher upside potential than BellRing Brands, Inc., analysts believe USANA Health Sciences, Inc. is more attractive than BellRing Brands, Inc..

USANA Health Sciences, Inc. has a beta of 0.648, which suggesting that the stock is 35.244% less volatile than S&P 500. In comparison BellRing Brands, Inc. has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.375%.

USANA Health Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BellRing Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. USANA Health Sciences, Inc. pays -- of its earnings as a dividend. BellRing Brands, Inc. pays out -- of its earnings as a dividend.

USANA Health Sciences, Inc. quarterly revenues are $213.7M, which are smaller than BellRing Brands, Inc. quarterly revenues of $648.2M. USANA Health Sciences, Inc.'s net income of -$6.7M is lower than BellRing Brands, Inc.'s net income of $59.6M. Notably, USANA Health Sciences, Inc.'s price-to-earnings ratio is 24.01x while BellRing Brands, Inc.'s PE ratio is 14.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for USANA Health Sciences, Inc. is 0.44x versus 1.38x for BellRing Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Herbalife Ltd. has a net margin of -3.12% compared to USANA Health Sciences, Inc.'s net margin of 3.38%. USANA Health Sciences, Inc.'s return on equity of 3.06% beat Herbalife Ltd.'s return on equity of --.

USANA Health Sciences, Inc. has a consensus price target of $39.00, signalling upside risk potential of 82.5%. On the other hand Herbalife Ltd. has an analysts' consensus of $14.00 which suggests that it could fall by -15.1%. Given that USANA Health Sciences, Inc. has higher upside potential than Herbalife Ltd., analysts believe USANA Health Sciences, Inc. is more attractive than Herbalife Ltd..

USANA Health Sciences, Inc. has a beta of 0.648, which suggesting that the stock is 35.244% less volatile than S&P 500. In comparison Herbalife Ltd. has a beta of 0.818, suggesting its less volatile than the S&P 500 by 18.193%.

USANA Health Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Herbalife Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. USANA Health Sciences, Inc. pays -- of its earnings as a dividend. Herbalife Ltd. pays out -- of its earnings as a dividend.

USANA Health Sciences, Inc. quarterly revenues are $213.7M, which are smaller than Herbalife Ltd. quarterly revenues of $1.3B. USANA Health Sciences, Inc.'s net income of -$6.7M is lower than Herbalife Ltd.'s net income of $43.1M. Notably, USANA Health Sciences, Inc.'s price-to-earnings ratio is 24.01x while Herbalife Ltd.'s PE ratio is 5.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for USANA Health Sciences, Inc. is 0.44x versus 0.34x for Herbalife Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

LifeVantage Corp. has a net margin of -3.12% compared to USANA Health Sciences, Inc.'s net margin of 4.53%. USANA Health Sciences, Inc.'s return on equity of 3.06% beat LifeVantage Corp.'s return on equity of 31.79%.

USANA Health Sciences, Inc. has a consensus price target of $39.00, signalling upside risk potential of 82.5%. On the other hand LifeVantage Corp. has an analysts' consensus of $17.00 which suggests that it could grow by 150.43%. Given that LifeVantage Corp. has higher upside potential than USANA Health Sciences, Inc., analysts believe LifeVantage Corp. is more attractive than USANA Health Sciences, Inc..

USANA Health Sciences, Inc. has a beta of 0.648, which suggesting that the stock is 35.244% less volatile than S&P 500. In comparison LifeVantage Corp. has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.888%.

USANA Health Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeVantage Corp. offers a yield of 3.02% to investors and pays a quarterly dividend of $0.05 per share. USANA Health Sciences, Inc. pays -- of its earnings as a dividend. LifeVantage Corp. pays out 21.85% of its earnings as a dividend. LifeVantage Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

USANA Health Sciences, Inc. quarterly revenues are $213.7M, which are larger than LifeVantage Corp. quarterly revenues of $47.6M. USANA Health Sciences, Inc.'s net income of -$6.7M is lower than LifeVantage Corp.'s net income of $2.2M. Notably, USANA Health Sciences, Inc.'s price-to-earnings ratio is 24.01x while LifeVantage Corp.'s PE ratio is 7.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for USANA Health Sciences, Inc. is 0.44x versus 0.33x for LifeVantage Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nature's Sunshine Products, Inc. has a net margin of -3.12% compared to USANA Health Sciences, Inc.'s net margin of 4.31%. USANA Health Sciences, Inc.'s return on equity of 3.06% beat Nature's Sunshine Products, Inc.'s return on equity of 9.26%.

USANA Health Sciences, Inc. has a consensus price target of $39.00, signalling upside risk potential of 82.5%. On the other hand Nature's Sunshine Products, Inc. has an analysts' consensus of $22.50 which suggests that it could fall by -6.68%. Given that USANA Health Sciences, Inc. has higher upside potential than Nature's Sunshine Products, Inc., analysts believe USANA Health Sciences, Inc. is more attractive than Nature's Sunshine Products, Inc..

USANA Health Sciences, Inc. has a beta of 0.648, which suggesting that the stock is 35.244% less volatile than S&P 500. In comparison Nature's Sunshine Products, Inc. has a beta of 0.935, suggesting its less volatile than the S&P 500 by 6.476%.

USANA Health Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nature's Sunshine Products, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. USANA Health Sciences, Inc. pays -- of its earnings as a dividend. Nature's Sunshine Products, Inc. pays out -- of its earnings as a dividend.

USANA Health Sciences, Inc. quarterly revenues are $213.7M, which are larger than Nature's Sunshine Products, Inc. quarterly revenues of $128.3M. USANA Health Sciences, Inc.'s net income of -$6.7M is lower than Nature's Sunshine Products, Inc.'s net income of $5.5M. Notably, USANA Health Sciences, Inc.'s price-to-earnings ratio is 24.01x while Nature's Sunshine Products, Inc.'s PE ratio is 29.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for USANA Health Sciences, Inc. is 0.44x versus 0.94x for Nature's Sunshine Products, Inc.. Usually stocks with elevated PS ratios are considered overvalued.